311 related articles for article (PubMed ID: 35741863)
1. Synthetic Lethality Targeting Polθ.
Drzewiecka M; Barszczewska-Pietraszek G; Czarny P; Skorski T; Śliwiński T
Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741863
[TBL] [Abstract][Full Text] [Related]
2. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
[TBL] [Abstract][Full Text] [Related]
3. Targeting Polymerase Theta (POLθ) for Cancer Therapy.
Patterson-Fortin J; D'Andrea AD
Cancer Treat Res; 2023; 186():285-298. PubMed ID: 37978141
[TBL] [Abstract][Full Text] [Related]
4. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
[TBL] [Abstract][Full Text] [Related]
5. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles of RAD52 and POLQ in chromosomal break repair and replication stress response.
Kelso AA; Lopezcolorado FW; Bhargava R; Stark JM
PLoS Genet; 2019 Aug; 15(8):e1008319. PubMed ID: 31381562
[TBL] [Abstract][Full Text] [Related]
7. Polymerase θ Coordinates Multiple Intrinsic Enzymatic Activities during DNA Repair.
Zahn KE; Jensen RB
Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573292
[TBL] [Abstract][Full Text] [Related]
8. Targeting the DNA Repair Enzyme Polymerase θ in Cancer Therapy.
Schrempf A; Slyskova J; Loizou JI
Trends Cancer; 2021 Feb; 7(2):98-111. PubMed ID: 33109489
[TBL] [Abstract][Full Text] [Related]
9. DNA Double Strand Break Repair - Related Synthetic Lethality.
Toma M; Skorski T; Sliwinski T
Curr Med Chem; 2019; 26(8):1446-1482. PubMed ID: 29421999
[TBL] [Abstract][Full Text] [Related]
10. Polθ is phosphorylated by PLK1 to repair double-strand breaks in mitosis.
Gelot C; Kovacs MT; Miron S; Mylne E; Haan A; Boeffard-Dosierre L; Ghouil R; Popova T; Dingli F; Loew D; Guirouilh-Barbat J; Del Nery E; Zinn-Justin S; Ceccaldi R
Nature; 2023 Sep; 621(7978):415-422. PubMed ID: 37674080
[TBL] [Abstract][Full Text] [Related]
11. DNA polymerase θ (POLQ), double-strand break repair, and cancer.
Wood RD; Doublié S
DNA Repair (Amst); 2016 Aug; 44():22-32. PubMed ID: 27264557
[TBL] [Abstract][Full Text] [Related]
12. RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.
Toma M; Sullivan-Reed K; Śliwiński T; Skorski T
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615159
[TBL] [Abstract][Full Text] [Related]
13. Targeting DNA Repair with Combined Inhibition of NHEJ and MMEJ Induces Synthetic Lethality in TP53-Mutant Cancers.
Patterson-Fortin J; Bose A; Tsai WC; Grochala C; Nguyen H; Zhou J; Parmar K; Lazaro JB; Liu J; McQueen K; Shapiro GI; Kozono D; D'Andrea AD
Cancer Res; 2022 Oct; 82(20):3815-3829. PubMed ID: 35972384
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
[TBL] [Abstract][Full Text] [Related]
15. Polymerase θ inhibition steps on the cGAS pedal.
Smith CM; Gupta GP
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37259920
[TBL] [Abstract][Full Text] [Related]
16. Synthetic lethality in DNA repair network: A novel avenue in targeted cancer therapy and combination therapeutics.
Bhattacharjee S; Nandi S
IUBMB Life; 2017 Dec; 69(12):929-937. PubMed ID: 29171189
[TBL] [Abstract][Full Text] [Related]
17. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Czyż M; Toma M; Gajos-Michniewicz A; Majchrzak K; Hoser G; Szemraj J; Nieborowska-Skorska M; Cheng P; Gritsyuk D; Levesque M; Dummer R; Sliwinski T; Skorski T
Oncotarget; 2016 Nov; 7(46):75551-75560. PubMed ID: 27705909
[TBL] [Abstract][Full Text] [Related]
18. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
19. POLQ inhibition elicits an immune response in homologous recombination-deficient pancreatic adenocarcinoma via cGAS/STING signaling.
Oh G; Wang A; Wang L; Li J; Werba G; Weissinger D; Zhao E; Dhara S; Hernandez RE; Ackermann A; Porcella S; Kalfakakou D; Dolgalev I; Kawaler E; Golan T; Welling TH; Sfeir A; Simeone DM
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 36976649
[TBL] [Abstract][Full Text] [Related]
20. POLθ-mediated end joining is restricted by RAD52 and BRCA2 until the onset of mitosis.
Llorens-Agost M; Ensminger M; Le HP; Gawai A; Liu J; Cruz-García A; Bhetawal S; Wood RD; Heyer WD; Löbrich M
Nat Cell Biol; 2021 Oct; 23(10):1095-1104. PubMed ID: 34616022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
